Methodological aspects of the evaluation of postoperative cancer surveillance. Part II: Efficacy

Clinical Laboratory

Volumn 49, Issue 7-8, 2003, Pages 379-398

  Abel, Ulrich ^a   Wollermann, C ^b  

^a Tumorzentrum Heidelberg/Mannheim   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

BONE SCINTISCANNING; BREAST CANCER; BREAST SURGERY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL SURGERY; COST EFFECTIVENESS ANALYSIS; EVALUATION; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; PATIENT MONITORING; POSTOPERATIVE CARE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; THORAX RADIOGRAPHY;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; META-ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE;

EID: 0042030972     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Abel U, Berger J. Comparison of resubstitution, data splitting, the Bootstrap, and the Jackknife as methods for estimating the validity indices of new marker tests. Biometrical J 1986; 28: 899-908
2. Abel U, Quentmeier A, Herfarth Ch. Monitoring plasma CEA in the follow-up of colorectal cancer: the validation of a class of diagnostic criteria for early detection of local recurrence and metastases. Theoret Surgery 1986; 1: 136-142
3. Abel U. Die Bewertung diagnostischer Tests. Stuttgart: Hippokrates-Verlag, 1993
4. Abel U, Windeler J. Erkenntnistheoretische Aspekte klinischer Studien. 1. Irrtümer in der Bewertung medizinischer Therapien - Ursachen und Konsequenzen. Internistische Praxis 1995; 35: 613-629
5. Abel U, Windeler J. Erkenntnistheoretische Aspekte klinischer Studien. 2. Die Wirksamkeit medizinischer Therapien. Internistische Praxis 1996; 36: 375-90
6. Abel U, Windeler J. Erkenntnistheoretische Aspekte klinischer Studien. 4. Vergleichbarkeit in klinischen Studien. A. "Strukturgleichheit" und die Bedeutung der Randomisation. Internistische Praxis 1998; 38: 613-24
7. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 1999; 52: 487-97
8. Abel U, Wollermann C. Die Bewertung von Tumor-Nachsorgemaßnahmen aus biometrischer Sicht. Forschungsbericht Nr. 41 der Abteilung Medizinische Biometrie, Universität Heidelberg, 2002
9. American Society for Gastrointestinal Endoscopy. Guidelines for colorectal cancer screening and surveillance. Gastrointestinal Endoscopy 2000; 51: 777-782
10. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncology 1996; 14: 2843-2877
11. American Society of Clinical Oncology. Recommended breast cancer surveillance guidelines. J Clin Oncol 1997; 15: 2149-2156
12. American Society of Clinical Oncology. Update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncology 1998; 16: 793-795
13. Anonymous. Krebsnachsorge: Abschied von Illusionen. Münch Med Wschr 1997; 139: 22-23
14. Anthony Th, Fleming JB, Cieligk SC et al. Postoperative colorectal cancer surveillance. J Am Coll Surg 2000; 190: 737-749
15. Audisio R, Setti-Carraro P, Segala M, Capko D, Andreoni B, Tiberio G. Follow-up in colorectal cancer patients: a cost-benefit analysis. Annals of Surgical Oncology 1996; 3: 349-357
16. Audisio RA, Robertson C. Colorectal cancer follow-up: perspectives for future studies. Europ. J Surgical Oncol 2000; 26: 329-337
17. Baker S, Kramer BS, Srivastava S. Markers for early detection of cancer. Statistical guidelines for nested case-control studies. BMC Medical Research Methodology [electronic resource] 2002; 2:4 www.biomedcentral.com/1471-2288/2/4
18. Barillari P, Ramacciato G, Manetti G, Bovino A, Sammartino P. Surveillance of colorectal cancer. Dis. Colon Rectum 1996; 38: 388-393
19. Bedenne L, Jouve JL. Surveillance des cancer colorectaux après exérèse. La Presse Médicale 1999; 28: 651-656
20. Berlin JA, Begg CB, Louis TA. An assessment of publication bias using a sample of published clinical trials. JAMA 1989; 84: 381-392
21. Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000; 355: 395-399
22. Bleeker WA, Mulder NH, Hermans J, Otter R, Plukker JTM. Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Brit J Surgery 2001; 88: 101-106
23. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surgery 1984; 8: 279-286
24. Böhm B, Schwenk W, Hucke HP, Stock W. Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum 1993; 36: 280-286
25. Brown L, Payne S, Royle G. Patient initiated follow-up of breast cancer. Psycho-Oncology 2002; 11: 356-355
26. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. Am J Roentgenol 1995; 165: 1373-77
27. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema DF, van de Velde CJH. Follow-up of patients with colorectal cancer:A meta-analysis. Annals of Surgery 1994; 219: 174-182
28. Camuñas J, Enriques JM, Devesa JM, Morales V, Milian I. Value of follow-up in the management of recurrent colorectal cancer. Europ J Surgical Oncology 1991; 17: 530-535
29. Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 2000; 92: 1657-66
30. Ciatto S, Muraca MC, Rosselli del Turco M. Survey of the practice of follow-up for the early detection of distant metastases in breast cancer patients in Europe. The Breast 1998; 7: 72-74
31. Cocconi G. Follow-up nel carcinoma colorettale. Tumori 2001; 87 (Suppl 1): S37-S38
32. Cohen AM, Paty P. CEA for monitoring colon cancer. Letter. JAMA 1994; 271: 346
33. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. Brit Med J 2000; 321: 531-535
34. Cooper GS, Yuan Z, Chak A, Rimm AA. Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for non-metastatic colorectal carcinoma. Cancer 1999; 85: 2124-2131
35. D'Angelica M, Brennan MF, Fortner JG, Cohen AM, Blumgart LH, Fong Y. Ninety-six five-year survivors after liver resection from metastatic colorectal cancer. J Am College of Surgeons 1997; 185: 554-559
36. Delbrück H, Bamberg M. La cure est morte! Vive la rehabilitation! Editorial. Onkologe 2000; 6: 1-2
37. Denstman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ, Riether RD. Comparing predictive decision rules in postoperative CEA monitoring. Cancer 1986; 58: 2089-2095
38. Desch CE, Benson III, AB, Smith TJ et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17: 1312-1321
39. Donnelly J, Mack P, Donaldson LA. Follow-up of breast cancer: time for a new approach. Int J Clin Pract 2001; 55: 431-433
40. Eckardt VF, Stamm H, Kanzler G, Bernhard G. Improved survival after colorectal cancer in patients complying with a postoperative endoscopic surveillance program. Endoscopy 1994; 26: 523-527
41. Eckardt VF, Bernhard G. Nachsorge beim kolorektalen Karzinom. Dt. Ärzteblatt 1997; 93A: 456-462
42. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. J Gen Intern Med 1997; 12: 318-331
43. Edelman MJ, Siegel D, Meyers FJ. Follow-up testing after cancer treatment: is it indicated? Western J Med 1998;168:528-529
44. Elmore J, Miglioretti DL, Reisch LM et al. Screening mammograms by community radiologists: variability in false-positive rates. J Natl Cancer Inst 2002a; 94: 1373-80
45. Elmore JG, Carney PA. Does practice make perfect when interpreting mammography? Editorial J Natl Cancer Inst 2002b; 94: 321-23
46. Emir B, Wieand S, Su JQ, Cha S. Analysis of repeated markers used to predict progression of cancer. Statist Med 1998; 17: 2563-2578
47. Esserman L, Cowley H, Eberle C et al. Improving the accuracy of mammography volume and outcome relationships. J Natl Cancer Inst 2002; 94: 369-75
48. Fletcher RH. Carcinoembryonic antigen. Ann. Internal Medicine 1986; 104: 66-73
49. Fletcher RH. CEA monitoring after surgery for colorectal cancer. When is the evidence sufficient? Editorial JAMA 1993; 270: 987-988
50. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85: 1644-56
51. Fossati R. Il follow-up del carcinoma colorettale operato radicalmente. Tumori 2001; 87 (Suppl. 1): S35-S36
52. Füeßl HS. Welche Nachsorge bei Mammakarzinom? Münch Med Wschr 1994; 136/Nr 26: S. 16
53. Gallmeier WM, Keding G. Nachsorge bei Krebspatienten. Münch Med Wschr 1994; 136: 610-616
54. Goldberg R, Fleming TR, Tangen CM et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Internal Medicine 1998; 129: 27-35
55. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer. Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Annals of Surgery 1998; 228: 59-63
56. Grunfeld E, Fitzpatrick R, Mant D et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Brit J of General Practice 1999; 49: 705-710
57. Gulliford T, Opumu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ 1997; 314: 174-177
58. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 2003
59. Jensen K, Abel U. Methodik diagnostischer Validierungsstudien - Fehler in der Studienplanung und Auswertung. Med Klinik 2000; 95, Sondernummer: 54-60
60. Kerlikowske K, Grady D, Barclay J et al. Likelihood ratios for modern screening mammography. J Am Med Assoc 1996; 276: 39-43
61. Kievit J, Bruinvels DJ. Detection of recurrence after surgery for colorectal cancer. Europ. J Cancer 1995; 31A: 1222-1225
62. Kievit J. Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness. Europ J Surgical Oncology 2000; 26: 322-328
63. Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Europ J Cancer 2002; 38: 986-999
64. Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J 1997; Surgery 84: 666-669
65. Kjeldsen BJ, Thorsen H, Whalley D, Kronborg O. Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand J Gastroenterol 1999; 34: 509-515
66. Kleeberg UR. Interview. (Behandlung von Krebspatienten in der Praxis). Cancer Care 1994; 1: 10-11
67. Köbberling J, Richter K, Trampisch HJ, Windeler J. Methodologie der medizinischen Diagnostik. Berlin Heidelberg New York: Springer, 1991
68. Kronborg O. Colorectal cancer follow-up. Editorial Europ J Surgical Oncol 2000; 26: 321
69. Langhammer HR, Ellgas W, Laubenbacher C et al. Ca 15-3 und CEA in der Rezidivdiagnostik des Mammakarzinoms unter Berücksichtigung von Lokalisation und Ausmaß der Metastasierung. TumorDiagnostik u. Therapie 1994; 15: 96-103
70. Lavin PT, Day J, Holyoke D, Mittelman A, Chu TM. A statistical evaluation of baseline and follow-up carcinoembryonic antigen in patients with resectable colorectal carcinaoma. Cancer 1981; 47: 823-826
71. Lennon T, Houghton J, Northover J. Post-operative CEA monitoring and second-look surgery in colorectal cancer: trial results. Abstract no 30. Br J Cancer 1994; 22 (Suppl.): 16
72. Liberati A, Torri V, Apolone G. Assessing the effectiveness of follow-up care for colorectal cancer: a great conceptual and methodological challenge for clinical oncology. Editorial Annals of Oncology 1997; 8: 1059-1062
73. Loprinzi CL. It is now the age to define the appropriate follow-up of primary breast cancer patients. Editorial J Clin Oncol 1994; 12: 881-883
74. MacKenzie S, O'Dwyer PJ. Surveillance after colorectal cancer resection. Letter. Lancet 2000; 355: 1095
75. Mäkelä JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Arch Surg 1995; 130: 1062-1067
76. Martin EW, James KK, Hurtubis PE, Catalano P, Minton JP. The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer 1977; 39: 440-446
77. McArdle C. ABC of colorectal cancer: Effectiveness of follow-up. BMJ 2000; 321: 1332-1335
78. McCall JL, Black RB, Rich CA et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37: 875-881
79. Millat B, Borie F. Faut-il surveiller les malades opérés d'un cancer colorectal? J Chir 1998; 135: 177-181
80. Mille D, Roy T, Carrère MO et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol 2000; 18: 1718-1724
81. Minton JP, Hoehn JL, Gerber DM et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284-1290
82. Moertel Ch, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 1990; 322: 352-358
83. Moertel C, Fleming T, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembyonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943-947
84. Moertel C. CEA for monitoring colon cancer. Letter to the Editor. JAMA 1994; 271: 346-347
85. Morrison AS. Screening in chronic disease. New York Oxford: Oxford Univ. Press, 1985
86. Müller JM, Schmidt A, Strauß JM, Zieren HU. Resektion von Lebermetastasen kolorektaler Karzinome. Anspruch und Wirklichkeit. Dt Med Wschr 1991; 116: 681-688
87. Müller JM, Tübergen D, Zieren U. Nachsorge beim kolo-rektalen Karzinom. Zentralbl Chir 1994; 119: 65-74
88. Muss HB. Management of metastatic breast cancer: current standards and emerging concept. (Online program certified by accredited CME providers). Transcript of a presentation as delivered by the faculty at the "Optimal Therapy for Primary and Metastaic Breast Cancer: Emergings Standards and New Approaches" Symposium, San Anonio, Texas, Dec 13, 2001. Seton Hall University School of Graduate Medical Education. 2002, www.medscape.com/viewprogram/1021t
89. Northover J. Realism or nihilism in bowel cancer follow-up? The Lancet 1998; 351: 1074-1076
90. Northover J. Which type of follow-up? Hepato-Gastroenterology 2000; 47: 335-336
91. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Annals of Oncology 1997; 8: 1081-1087
92. O'Dwyer PJ, Stevenson JP, Haller DG, Rotman N, Giantonio BJ. Follow-up of stage B and C colorectal cancer in the United States and France. Seminars in Oncology 2001; 28 (Suppl. 1): 45-49
93. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Dis Colon Rectum 1995; 38: 619-626
94. Ostendorf GM. Krebs-Nachsorge: Trend zur individuellen Betreuung. 1999; http://arzt-online.de/docs/1999/04/09/065a1501.asp
95. Otten JDM, van Dijck JAAM, Peer PGM et al. Long-term breast cancer screening in Nijmegen, The Netherlands: the nine rounds from 1975-92. J. Epidemiology and Community Health 1996; 50: 353-358
96. Palli D, Russo A, Saieva C et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10 year update of a randomized trial. JAMA 1999; 281: 1586
97. Pandya KJ, McFadden ET, Kalish LA, Tormey DC, Taylor SG, Falkson G. A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. Cancer 1985; 55: 202-205
98. Peethambaram P, Weiss M, Loprinzi CL et al. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure. Oncology 1997; 54: 287-292
99. Pichlmaier H. Kosten-Nutzen-Überlegungen in der onkologischen Chirurgie, Münch Med Wschr 1994; 136: 226-230
100. Pietra N, Sarli L, Costi R, Ouchemi C, Gratarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer. Dis Colon Rectum 1998; 41: 1127-1133
101. Poston G. The argument for liver resection in colorectal liver metastases. Hepato-Gastroenterology 2001; 48: 345-346
102. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. New engl J Med 1978; 299: 926-930
103. Reitzig P. Tumornachsorge - Nutzen oder sinnloser Aufwand? In: H. Günther, G. Ehninger (Hrsg.): Individuelle Therapieent-scheidungen bei "unbegrenzten Möglichkeiten". Dobersdorf : Pechstein Verlag, 1995: 111-119
104. Renehan A, O'Dwyer ST. A selective policy in follow-up for bowel cancer. Letter to the Editor. Lancet 1998; 351: 1891
105. Renehan A, O'Dwyer ST. Surveillance after colorectal cancer resection. Correspondence. Lancet 2000; 355: 1095-1096
106. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324: 1-8
107. Richard CS, McLeod RS Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons. Canadian J Surg 1997; 40: 90-100
108. Rojas MP, Telaro E, Russo A et al. Follow-up strategies for women treated for early breast cancer. (Cochrane Review): In: The Cochrane Library, Issue 1, Oxford: Update Software, 2003.
109. Rosen M, Chan L, Beart RW, Vukasin P, Anthone G. Follow-up of colorectal cancer. A meta-analysis. Dis Colon Rectum 1998; 41: 1116-1126
110. Rosselli del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 1994; 271: 1593-1597
111. Royall RM Current advances in sampling theory: implications for human observational studies. Am J Epidemiol 1976; 104: 463-474
112. Safi F, Beger HG. Ist die Tumornachsorge beim kolorektalen Karzinom sinnvoll? Dt Med Wschr 1991; 116,:1001-1007
113. Sakorafas GH, Tsiotou AG, Pavlakis G. Follow-up after primary treatment for breast cancer. Acta Oncologica 2000; 39: 935-940
114. Sauer J. (Hrsg.) Empfehlungen zur Diagnostik, Therapie und Nachsorge. Mammakarzinome. 8. überarbeitete Auflage 2001. Tumorzentrum München. 2001, http://www.krebsinfo.de/ki/empfehlung/mamma
115. Scanlon EF, Oviedo MA, Cunningham MP et al. Preoperative and follow-up procedures on patients with breast cancer. Cancer 1980; 46: 977-979
116. Schapira DV. Breast cancer surveillance: a cost-effectiveness strategy. Breast Cancer Res Treatm 1993; 25: 107-111
117. Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Archives of Surgery 1999; 384: 313-327
118. Schmid L, Sauer H. Neue Empfehlungen für die Mammakarzinom-Nachsorge. Münch Med Wschr 1994; 136: 413-414
119. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114: 7-14
120. Schumacher T, Schmitz S, Diehl V. Prognoserelevanz der onkologischen Nachsorge. Versicherungsmedizin 1995; 47: 166-170
121. Secco GB, Fardelli R, Gianquinto D et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surery: a prospective, randomized and controlled trial. Europ J Surgical oncology 2002; 28: 418-423
122. Shen Y, Zelen M. Parametric estimation procedures for screening programmes: Stable and nonstable disease models for multimodality case finding. Biometrika 1999; 86: 503-515
123. Smith TJ, Bear HD. Standard follow-up of colorectal cancer patients: finally we can make practice guidelines based on evidence. Gastroenterology 1998; 114: 211-213
124. Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surgery 1985; 149: 198-204
125. Staib L, Link KH, Beger HG. Follow-up in colorectal cancer: cost-effectiveness analysis of established and novel concepts. Langenbeck's Arch Surg 2000; 385: 412-420
126. Steele Jr G, Zamcheck N, Wilson R et al. Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surgery 1980; 139: 544-548
127. Taylor I. Quality of follow-up of the cancer patient affecting outcome. Surgical Oncology Clinics of North America 2000; 9: 21-25
128. The Givio Investigators Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 1994; 271: 1587-1592
129. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1992; 7: 1437-1446
130. Virgo K, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995; 273: 1837-1841
131. Wanebo HJ, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surgery Gynecology & Obstetrics 1989; 169: 479-487
132. Winchester DP, Sener SF, Khandekar JD et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 1979; 43: 956-960
133. Windeler J. Argumentationsstrukturen bei der Veneidigung nicht wissenschaftlich begründeter Verfahren in der Medizin. In: Köbberling, J. (Hrsg.): Die Wissenschaft in der Medizin. Stuttgart New York: Schattauer, 1992: 83-114
134. Wolf RF, Cohen AM. The minuscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer. J Am College of Surgeons 1997; 185: 60-64
135. Wood CB, Ratcliffe JG, Burt RW, Malcolm AJH, Blumgart LH. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surgery 1980; 67: 46-48